Masimo (NASDAQ:MASI) Issues FY24 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $3.95-$4.10 for the period, compared to the consensus EPS estimate of $3.88. The company issued revenue guidance of $2.075-$2.105 billion, compared to the consensus revenue estimate of $2.10 billion. Masimo also updated its Q4 2024 guidance to 1.350-1.500 EPS.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on MASI shares. BTIG Research boosted their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler restated an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $145.33.

Masimo Trading Up 2.8 %

MASI traded up $4.17 during trading on Tuesday, hitting $151.56. 1,309,948 shares of the stock were exchanged, compared to its average volume of 675,776. Masimo has a 1 year low of $75.36 and a 1 year high of $153.93. The firm has a market cap of $8.06 billion, a price-to-earnings ratio of 103.10 and a beta of 0.97. The firm has a 50 day simple moving average of $130.02 and a 200 day simple moving average of $125.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period in the previous year, the company posted $0.62 earnings per share. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. As a group, equities analysts expect that Masimo will post 3.88 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.